Stock Price & Analysis

The S1 support level for ERAS Stock is $1.26 ,The R1 resistant level for ERAS Stock is $1.5.

As of the end of day on 2025-03-06, the price of ERAS Stock was $1.395.

The target price for ERAS Stock according to analyst rating is 5.00, with the highest price target at 5.00 and the lowest at 5.00. Analysts have a Moderate Buy rating on ERAS Stock overall.

The market cap of ERAS is $401.5M.

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline including 12 disclosed modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. The Company’s pipeline includes five clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, a SHP2 inhibitor, an EGFR inhibitor, and a central nervous system (CNS)-penetrant KRAS G12C inhibitor, and seven discovery-stage programs targeting other key oncogenic drivers. The Company’s lead product candidate is naporafenib, designed to be a reversible, potent and selective ATP-competitive type 2 pan-RAF kinase inhibitor.

ERAS has a total of 126 employees.